As one of the most prevalent histological subtypes of lung cancer, lung adenocarcinoma accounts for approximately 40% of newly diagnosed lung cancer cases. Despite the significant improvements in clinical outcomes achieved by current comprehensive therapies (including surgery, chemotherapy, and targeted therapy), its 5-year survival rate remains around 15%, indicating that the oncogenic mechanisms underlying lung adenocarcinoma require further in-depth exploration. To uncover the key molecular mechanisms driving the progression of lung adenocarcinoma, this study has identified a long non-coding RNA (LncRNA).